Department of Reproductive Medicine and Child Development, Division of Obstetrics and Gynecology, University of Pisa, Pisa, Italy.
Gynecol Endocrinol. 2013 Apr;29(4):375-9. doi: 10.3109/09513590.2012.743020. Epub 2013 Jan 22.
To evaluate the effects the administration of myo-inositol (MYO) on hormonal parameters in a group of polycystic ovary syndrome (PCOS) patients.
Controlled clinical study.
PCOS patients in a clinical research environment.
50 overweight PCOS patients were enrolled after informed consent.
All patients underwent hormonal evaluations and an oral glucose tolerance test (OGTT) before and after 12 weeks of therapy (Group A (n¼10): MYO 2 g plus folic acid 200 mg every day; Group B (n¼10): folic acid 200 mg every day). Ultrasound examinations and Ferriman-Gallwey score were also performed.
Plasma LH, FSH, PRL, E2, 17OHP, A, T, glucose, insulin, C peptide concentrations, BMI, HOMA index and glucose-to-insulin ratio.
After 12 weeks of MYO administration plasma LH, PRL, T, insulin levels and LH/FSH resulted significantly reduced. Insulin sensitivity, expressed as glucose-to-insulin ratio and HOMA index resulted significantly improved after 12 weeks of treatment. Menstrual cyclicity was restored in all amenorrheic and oligomenorrheic subjects. No changes occurred in the patients treated with folic acid.
MYO administration improves reproductive axis functioning in PCOS patients reducing the hyperinsulinemic state that affects LH secretion.
评估肌醇（MYO）给药对多囊卵巢综合征（PCOS）患者激素参数的影响。
对照临床试验。
PCOS 患者在临床研究环境中。
50 名超重 PCOS 患者在知情同意后入组。
所有患者均在治疗前和治疗 12 周后进行激素评估和口服葡萄糖耐量试验（OGTT）（A 组（n=10）：每天 MYO 2 克加叶酸 200 毫克；B 组（n=10）：每天叶酸 200 毫克）。还进行了超声检查和 Ferriman-Gallwey 评分。
血浆 LH、FSH、PRL、E2、17OHP、A、T、葡萄糖、胰岛素、C 肽浓度、BMI、HOMA 指数和葡萄糖胰岛素比。
MYO 给药 12 周后，血浆 LH、PRL、T、胰岛素水平和 LH/FSH 显著降低。治疗 12 周后，胰岛素敏感性（以葡萄糖胰岛素比和 HOMA 指数表示）显著改善。所有闭经和稀发月经的患者均恢复月经周期。接受叶酸治疗的患者没有变化。
MYO 给药可改善 PCOS 患者的生殖轴功能，降低影响 LH 分泌的高胰岛素血症状态。
